Seminars in Hematology
Volume 43 , Pages S33-S36 , January 2006

Glanzmann’s Thrombasthenia Treatment: A Prospective Observational Registry on the Use of Recombinant Human Activated Factor VII and Other Hemostatic Agents

  • Man-Chiu Poon

      Affiliations

    • University of Calgary, Southern Alberta Hemophilia Clinic, Calgary Health Region, and Canadian Blood Services, Calgary, Canada.
    • Corresponding Author InformationAddress correspondence to Man-Chiu Poon, MD, University of Calgary, Foothills Hospital, 1403 29th Street NW, Calgary, Alberta, Canada T2N 2T9.
    • ,
  • Rainer Zotz

      Affiliations

    • Heinrich-Heine-Universität, Düsseldorf, Germany.
    • ,
  • Giovanni Di Minno

      Affiliations

    • Universita’ degli Studi di Napoli Federico II, IRCCS “Casa Sollievo della Sofferenza” S. Giovanni Rotondo, Italy.
    • ,
  • Zvika S. Abrams

      Affiliations

    • Novo Nordisk A/S, Bagsvaerd, Denmark.
    • ,
  • Jens B. Knudsen

      Affiliations

    • Novo Nordisk A/S, Bagsvaerd, Denmark.
    • ,
  • Yves Laurian

      Affiliations

    • AP-HP & UFR Medicine Paris XIII, Paris, France.

References 

  1. George JN , Caen JP , Nurden AT . Glanzmann’s thrombasthenia (The spectrum of clinical disease) . Blood . 1990;75:1383–1395
  2. Nurden AT . Inherited abnormalities of platelets . Thromb Haemost . 1999;82:468–480
  3. Levy-Toledano S , Tobelem G , Legrand C , Bredoux R , Degos L , Nurden A , et al.  Acquired IgG antibody occurring in a thrombasthenic patient (Its effect on human platelet function) . Blood . 1978;51:1065–1071
  4. Vrielink H , Reesink HW . Transfusion-transmissible infections . Curr Opin Hematol . 1998;5:396–405
  5. Poon MC , d’Oiron R , Von Depka M , Khair K , Negrier C , Karafoulidou A , et al.  Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann’s thrombasthenia (Results of an international survey) . J Thromb Haemost . 2004;2:1096–1103
  6. Tengborn L , Petruson B . A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa . Thromb Haemost . 1996;75:981–982 (letter)
  7. Poon M-C , Demers C , Jobin F , Wu JW . Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia . Blood . 1999;94:3951–3953
  8. Musso R , Cultrera D , Russo M , Giuffrida G , Venturino L , Ferlito C , et al.   Recombinant activated factor VII as haemostatic agent in Glanzmann’s thrombasthenia . Thromb Haemost . 1999;82(suppl):621; (abstr)
  9. Robinson KL , Savoia H , Street AM . Thrombotic complications in two patients receiving NovoSeven . Haemophilia . 2000;6:349; (abstr)
  10. d’Oiron R , Menart C , Trzeciak MC , Nurden P , Fressinaud E , Dreyfus M , et al.  Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann’s thrombasthenia undergoing invasive procedures . Thromb Haemost . 2000;83:644–647
  11. Almeida AM , Khair K , Hann I , Liesner R . The use of recombinant factor VIIa in children with inherited platelet function disorders . Br J Haematol . 2003;121:477–481
  12. Devecioglu O , Unuvar A , Anak S , Bilge I , Ander H , Ziylan O . Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies (the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions) . Turk J Pediatr . 2003;45:64–66
  13. Okie S . Safety in numbers—Monitoring risk in approved drugs . N Engl J Med . 2005;352:1173–1176

PII: S0037-1963(05)00216-7

doi: 10.1053/j.seminhematol.2005.11.009

Seminars in Hematology
Volume 43 , Pages S33-S36 , January 2006

Article Tools